The AI Tension in Healthcare: Patent Strategy, FDA Reality, and HIPAA Constraints
These three legal regimes are pulling in different directions, and the developers that navigate them well will be the ones that plan for all three from the start.
Why Settle for Acceptable Versus Optimal Outcomes?
New 3D printed technology makes lower extremity surgeons architects of restoration, not adaptation.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Why the Next Era of Sleep Medicine Depends on Better Diagnostics
Matching the right patient to the right therapy now requires understanding what’s driving the apnea, not just how often it occurs. Closing that gap means rethinking what sleep apnea testing identifies and where it happens.
This Ear-Based Device Could Save Patients from Brain Bleed Complications
Aurenar's V-Link, a non-invasive nerve stimulation device for preventing brain hemorrhage complications, just won FDA breakthrough device designation after early trials showed it cut cerebral vasospasm by more than 40%.
FDA Approves First Neurostimulation Device for PTSD
Neurovalens' Modius Spero has become the first FDA-approved neuromodulation device for treating PTSD symptoms. Veterans are set to gain access through the VA this summer.
Xella Health Emerges from Stealth to Give Women Answers the Healthcare System Hasn’t
Women’s health platform Xella Health launched with a $499-per-year membership. The platform provides women the kind of connected healthcare that has typically only been available through expensive concierge medicine, said CEO Kelly Lacob.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Researchers Say Whole-Body MRI Companies Are Inflating the Scans’ Medical Benefits
A recent JAMA editorial from two radiologists argues that elective whole-body MRI scan companies are misleading consumers about the benefits of said scans. The radiologists argue the MRIs are more likely to trigger harmful downstream procedures than they are to save lives. Not surprisingly, the three most prominent companies offering these scans denied the charge.
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
Combined upper and lower GI endoscopy is becoming standard practice across many US healthcare settings, but the quality infrastructure for upper GI has not kept pace with the procedures now being performed on it.
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak
Verily is testing wastewater across World Cup host cities for pathogens like RSV, measles and norovirus, aiming to spot outbreaks five to seven days before they show up in clinics.
It’s Time for Technology to Lift Maternal Care
Improving maternal safety will not come from adding more data or more devices. It will come from building systems that help clinicians recognize risk earlier and communicate and act with confidence in the moment.
presented by
New Webinar: The Payer AI Readiness Gap: Why Better Data Will Define the Next Era of Health Plan Performance
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward
Contraline raised $92.5 million in new funding to advance its two male contraceptive candidates, including a once-daily topical gel and an implantable option.
CereVasc Rakes In $85M to Challenge Traditional Brain Shunt Surgery
CereVasc raised $85 million in Series C funding to advance its minimally invasive eShunt system, which aims to treat hydrocephalus without traditional brain shunt surgery. The company is preparing for a pivotal trial completion and FDA submission in 2027.
The Celiac Care Gap Begins After Diagnosis
Portable gluten detection tools are not a substitute for standard care. Used carefully, they may help clinicians support patients when hidden gluten exposure remains a problem.
Are We Measuring Metabolic Health All Wrong?
A fragmented system built on isolated metrics like BMI and A1C fails to capture the full picture of metabolic health and limits our ability to manage it effectively.
Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss
Signos raised $20 million to expand its glucose monitoring platform for weight loss, which pairs Dexcom’s over-the-counter CGM with an app that translates glucose data into personalized diet and lifestyle recommendations.